Review of Superior Vena Cava Resection in the Management of ...

GENERAL THORACIC

Review of Superior Vena Cava Resection in the Management of Benign Disease and Pulmonary or Mediastinal Malignancies Michael Lanuti, MD, Pierre E. De Delva, MD, Henning A. Gaissert, MD, Cameron D. Wright, MD, John C. Wain, MD, James S. Allan, MD, Dean M. Donahue, MD, and Douglas J. Mathisen, MD Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts

Background. Obstruction of the superior vena cava (SVC) by tumor or benign disease implies unreconstructable disease and poor outcome. We analyzed the operative results, graft patency, and survival in patients undergoing SVC resection and reconstruction for benign disease and pulmonary or mediastinal malignancy. Methods. Patients undergoing SVC resection from 1997 to 2007 for surgical management of benign and invasive neoplasms were retrospectively reviewed. Results. We identified 19 patients requiring SVC resection. Malignant disease was resected in 17: lung cancer in 9 and mediastinal malignancy in 8. Two patients (10%) with benign processes required reconstruction for chronic SVC syndrome. Ringed Gore-Tex conduit (W. L. Gore and Associates, Flagstaff, AZ) was used for 12 reconstructions (63%) of the SVC, and 7 patients underwent primary closure or autologous pericardial patch

repair. Preoperative chemoradiotherapy was administered to 9 patients (53%). There was one perioperative death (5%). Major postoperative morbidities included atrial fibrillation in 5, stroke in 2, respiratory failure in 3, myocardial infarction in 1, and Horner syndrome in 1. Median survival for the entire cohort was 45.5 months (range, 0.2 to 147 months), with a mean follow-up of 45.8 months. Five-year survival probability was 30% for patients with resected lung cancer and 56% for patients with resected anterior mediastinal malignancies. Conclusions. Resection and reconstruction may be safely performed in selected patients for benign and malignant obstruction or infiltration of the SVC. Survival and intermediate-term patency after tubular grafting of the SVC are acceptable. (Ann Thorac Surg 2009;88:392– 8) © 2009 by The Society of Thoracic Surgeons

T

taken into account the potential resectability and different prognosis of T4 N0-1 M0 and transferred these tumors to stage IIIA [8]. The feasibility and low morbidity of extended resection for pulmonary or mediastinal tumors infiltrating the SVC are well documented, but the selection of optimal candidates for aggressive resection is less well defined. Although some prognostic factors have been reported [9], ambiguity remains. Completeness of resection, extent of SVC involvement, and the presence of mediastinal lymph node metastases are all regarded as important in the evaluation of these select patients. There is little contention about SVC resection for anterior mediastinal tumors, but SVC resection in the context of NSCLC with nodal metastasis remains controversial. This study evaluates the outcomes of a heterogeneous group of patients undergoing en bloc SVC resection as part of an R0 resection of malignant disease of the lung and anterior mediastinum.

he superior vena cava (SVC) is susceptible to invasion from tumors arising from the anterior mediastinal compartment, such as thymomas, thymic carcinoma, thyroid neoplasms and germ cell tumors, as well as right-sided pulmonary neoplasms. Extended resection for SVC invasion (T4 disease) of non-small cell lung cancer (NSCLC) and anterior mediastinal neoplasms often evokes controversy about its long-term benefit but has been associated more recently with acceptable morbidity and survival in published series [1, 2]. The reported 5-year survival rate after SVC resection and reconstruction for lung cancer is 21% to 31% [3, 4] and for anterior mediastinal neoplasms is 45% to 53% [5, 6]. With regard to lung cancer, the results of tumors involving the SVC are far better than one would predict with stage IIIB NSCLC, with a historical survival of 6% to 8% [7]. The proposed 2009 revision (7th edition) of the T N M classification of lung cancer by the International Association for the Study of Lung Cancer (IASLC) has

Accepted for publication April 16, 2009. Presented at the Poster Session of the Forty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Francisco, CA, Jan 26 –28, 2009. Address correspondence to Dr Lanuti, 55 Fruit St, Blake 1570, Boston, MA 01748; e-mail: [email protected].

© 2009 by The Society of Thoracic Surgeons Published by Elsevier Inc

Material and Methods This study was approved by the Institutional Review Board (IRB) at the Massachusetts General Hospital. The IRB specifically considered this retrospective records 0003-4975/09/$36.00 doi:10.1016/j.athoracsur.2009.04.068

LANUTI ET AL SVC RESECTION FOR BENIGN AND MALIGNANT DISEASE

393

Fig 1. (A) Tangential superior vena cava (SVC) resection with primary repair. (B) Patch repair with bovine or autologous pericardium, (C) SVC replacement with ringed polytetrafluoroethylene graft (Gore-Tex) to left brachiocephalic vein. (Reprinted, with permission, from [10] Garcia A, Flores RN. Surgical management of tumors invading the superior vena cava. Ann Thorac Surg 2008;85:2144 – 6.)

review, including subject selection and confidentiality, and waived the need for patient consent.

Patients The study population included consecutive patients undergoing SVC resection and reconstruction for treatment of benign or malignant disease on the Thoracic Surgery Service at the Massachusetts General Hospital between January 1997 and December 2007. Retrospective medical record reviews were performed. The specific objective of the study was to evaluate the outcomes of radical resection for disease involving the SVC. The study included all patients who underwent SVC resection for pulmonary, mediastinal, or thyroid malignancies, as well as 2 patients with SVC syndrome from obstructive benign disease. No patient required extracorporeal bypass to achieve resection. The study was inclusive of all surgical approaches that provided suitable access, including median sternotomy, cervical sternotomy, and thoracotomy. Demographic, preoperative, intraoperative, and outcome measures were recorded. Data were obtained from the medical records, including office records, anesthesia records, and in-hospital records. Preoperative assessment included clinical examination, diagnostic imaging, pulmonary function, quantitative ventilation-perfusion scan (for pneumonectomy), bronchoscopy, and mediastinoscopy in most patients with NSCLC. Aside from diagnostic chest computed tomography, metastatic survey was performed with brain magnetic resonance imaging (MRI), bone scan, and when available beginning in about 2000, whole-body positron emission tomography (PET). Echocardiography was routinely used to fully evaluate biventricular function and rule out severe tricuspid regurgitation.

Operative Repair The degree of SVC infiltration dictated the type of resection. Primary repair was achieved in 5 patients when less than 50% of caval circumference was resected. Suture repair was conducted with running polypropylene suture, usually by tangential placement of a partial occlusion clamp. Larger defects were repaired in 2 patients using an autologous pericardial patch (Fig 1A and B). In 12 patients in whom SVC infiltration encompassed more than 50% of the vessel, the SVC was replaced with a ringed polytetrafluoroethylene (PTFE) graft (median size, 14 mm; sometimes reconstructed using technique in Fig 1C). Temporary interruption of flow during prosthetic replacement with proximal and distal caval clamps was managed with intravascular fluid expansion, lower extremity venous access, hyperventilation to reduce vasogenic cerebral edema, reverse Trendelenburg position, and vasoactive agents to elevate cerebral profusion pressure. The graft was introduced onto the operative field. The distal SVC anastomosis was performed first using 4-0 proline suture. This anastomosis is then tested for any leak. The proximal venous anastomosis is subsequently performed, and air was removed from the conduit before tying down the last anastomotic suture. Some resections included the brachiocephalic veins. There was a preference to reconstruct only one of the veins. All patients received intravenous heparin sodium (50 to 100 U/kg) 5 to 10 minutes before vascular occlusion. After intraoperative heparinization, the partial thromboplastin time (PTT) was allowed to normalize without pharmacologic reversal. Patients were selectively transitioned to an antiplatelet agent or Coumadin (Bristol-

GENERAL THORACIC

Ann Thorac Surg 2009;88:392– 8

GENERAL THORACIC

394



Table 1. Patient and Operative Characteristics

Table 2. Histology of Resected Neoplasms

Characteristic

Histology

Age, mean ⫾ SD, y Prosthetic graft reconstruction, No. (%) Partial resection, No. (%) Acute graft thrombosis, No. (%) Follow-up, median ⫾ SD, mon Overall morbidity, No. (%) 30-day mortality, No. (%) Non-small cell lung cancer Survival, median ⫾ SD, mon 5-year survival, % Anterior mediastinal neoplasms Survival, median ⫾ SD, mon 5-year survival, %

63 ⫾ 13 12 (63) 7 (37) 2 (10) 45.5 ⫾ 15.5 12 (63) 1 (5) 21.4 ⫾ 15.4 30 64.5 ⫾ 4.1 56

SD ⫽ standard deviation.

Myers Squibb, Princeton, NJ) at the surgeon’s discretion. Most patients with a PTFE vascular reconstruction received anticoagulation therapy for a minimum of 3 months.

Statistical Analysis Survival curves were constructed using the KaplanMeier method and compared with the log-rank test. Survival analyses were calculated with SPSS 14.0 software (SPSS Inc, Chicago, Ill). Comparisons of survival were performed for patients undergoing neoadjuvant therapy, nodal status in resected NSCLC, and tumor location.

Results From January 1997 to 2007, 19 patients (10 men) underwent SVC resection for treatment of locally invasive

Fig 2. Kaplan-Meier curves show overall survival of 17 patients who underwent superior vena cava resection for malignant disease.

Non-small cell lung cancer Adenocarcinoma Adenosquamous cell carcinoma Squamous cell carcinoma Epithelioid hemangioendothelioma Poorly differentiated carcinoma Mediastinal tumors Thyroid carcinoma Thymic carcinoma Germ cell neoplasm Primary adenocarcinoma Benign disease

No. (%) 9 3 (33) 1 (11) 3 (33) 1 (11) 1 (11) 8 3 (38) 3 (38) 1 (12) 1 (12) 2

disease. Patients were aged 41 to 82 years (Table 1). Of these, 17 patients (90%) had malignant disease, 1 had an intravascular lipoma associated with SVC syndrome, and another had fibrosing mediastinitis from histoplasmosis. The indication for SVC resection was direct invasion by tumor or relief of SVC obstruction from a malignant or benign process. Complete resection (R0) was achieved in all malignant cases. There were no intraoperative deaths. Resections were for NSCLC in 9 patients (47%), and the remainder were for invasive disease associated with thymic in 3, thyroid in 3, germ cell in 1, and a primary mediastinal neoplasm in 1. Mean follow-up for the entire cohort (excluding benign disease) was 46 ⫾ 15.5 months, with a survival probability of 41% at 5 years and 27% at 10 years (Fig 2). In patients with lung cancer, resections were performed through a right thoracotomy. Staging mediastinoscopy was performed in 7 of 9 patients (78%) with lung cancer. Ipsilateral N2 disease was confirmed in 2 of 7 patients and treated with induction chemoradiotherapy.

Fig 3. Kaplan-Meier curves show comparison of overall survival of 9 patients with resected non-small cell lung cancer (NSCLC, dotted line) and 8 patients with anterior mediastinal tumors (solid line); p ⫽ 0.588.

Fig 4. Kaplan-Meier curves show overall survival of resected lung cancer stratified by nodal T N M stage of N0 (black line), N1 (dotted line), and N2 (dashed line).

Surgical staging of the mediastinum was not performed in 2 patients. One patient received preoperative chemoradiotherapy where restaging PET showed no fluorine-18 fluoro-2-deoxy-D-glucose (FDG) activity in the mediastinal nodes. Another patient underwent right carinal pneumonectomy with no FDG activity in the mediastinum save for the tumor itself. Pulmonary resections included right intrapericardial pneumonectomy in 3, right carinal pneumonectomy in 1, right upper lobe sleeve lobectomy in 2, bilobectomy in 1, and middle lobectomy in 1. The histology of the resected tumors is listed in Table 2. One patient had T3 N1 disease with direct extension of hilar lymph nodes abutting the SVC requiring partial resection with primary repair. Metastatic ipsilateral mediastinal lymph node disease (T4 N2) was present in 3 patients, all of whom have died (mean survival, 13.2 months). Pathologic T4 N0 disease was documented in 3 patients, and T4 N1 disease in 1. Median survival for patients with lung cancer undergoing en bloc SVC resection was 21.4 months (range, 4.6 to 147.4 months), with a 5-year survival probability of 30% (Fig 3). Patients with T N M stage N2 disease had a trend toward worse survival (p ⫽ 0.089; Fig 4); however, when node-negative resections (N0) were compared with node-positive (N1-2) resections, the survival difference was statistically significant (p ⫽ 0.040). Median sternotomy was the most common approach to anterior mediastinal tumors. These tumors consisted of Hürthle cell carcinoma, anaplastic thyroid cancer, germ cell neoplasm, thymic carcinoma, and primary mediastinal carcinoma. Median survival for resected neoplasms of the anterior mediastinum was 64.5 months (range, 0.2 to 123 months), with a 5-year survival probability of 56% (Fig 3). Induction chemoradiotherapy was completed in 3 of 9 patients (33%) with NSCLC and in 6 of 8 (75%) with


395

anterior mediastinal malignancy. Adjuvant chemotherapy was administered to 5 of 9 patients (56%) with resected lung cancer. There was no significant survival difference between patients receiving induction chemoradiotherapy and those undergoing primary resection, followed by adjuvant therapy. Partial SVC resection was performed in 7 of 19 patients (37%), and an autologous pericardial patch was used for reconstruction in 2. Ringed PTFE grafts (size range, 8 to 18 mm) were used to reconstruct 12 SVC resections (63%), including ligation of a unilateral brachiocephalic vein in 5 patients. Symptomatic acute thrombosis of the SVC repair occurred in 2 patients (10%) early in the postoperative period (Table 1). One patient underwent SVC embolectomy within 24 hours with no further sequelae, and another patient with a resected intravascular SVC lipoma (primary SVC repair) was treated with anticoagulation, with resolution of upper extremity edema. Twelve patients (63%) were discharged with Coumadin therapy. Two patients had preoperative SVC thrombosis. Bronchial stumps after pneumonectomy were selectively covered with vascularized tissue, including pericardial fat, omental transposition, or intercostal muscle. One postoperative death occurred within 30-days in a patient with anaplastic thyroid cancer who underwent thyroidectomy with right brachiocephalic and partial SVC resection. Major complications in the 19 patients were atrial fibrillation in 5 (26%), respiratory failure in 3 (16%), stroke in 2 (11%), early SVC thrombosis in 2 (11%), and 1 patient (5%) each with Horner syndrome, postoperative myocardial infarction, and acute respiratory distress syndrome. SVC venous occlusion time associated with 12 circumferential resections was 50 minutes or less in all patients, with one exception. The need to replace the SVC was unanticipated preoperatively in one patient, and bleeding during dissection required SVC clamping for a prolonged period. This resulted in bilateral posterior ischemic optic neuropathy. The visual loss eventually improved over many months.

Comment The selection of appropriate candidates for extended resection of pulmonary and anterior mediastinal neoplasms involving the SVC remains challenging. Preoperative diagnostic imaging, including fusion CT-PET, CT venography, and gated cardiac MRI, has improved our ability to stage tumors and predict resectable disease. Pathologic staging with mediastinoscopy, endobronchial ultrasound transbronchial lymph node biopsy, or thoracoscopy is paramount in determining a multimodality strategy in these heterogeneous patients. Evidence for improved outcome after extended surgical resection for multistation N2 or bulky (⬎ 2 cm in short-axis diameter) N2 disease in NSCLC is lacking [11], and patients with this stage should be very carefully selected. Earlier studies examining SVC resection for infiltrating malignant disease do not consistently document details of preoper-

GENERAL THORACIC


GENERAL THORACIC

396


ative staging, thus weakening conclusions about nodal disease and outcomes [2, 9, 12]. Although this study has a small sample size and is underpowered for any meaningful statistical analysis, the presence of nodal disease (N1-2) in resected NSCLC was significant (p ⫽ 0.04) for predicting poor long-term survival compared with node-negative disease (N0). This intuitive observation was corroborated in studies by Dartevelle and colleagues [3] in 1991, Suzuki and colleagues [4] in 2004, and Spaggiari and colleagues [5] in 2007. Spaggiari and colleagues reported a 5-year survival of 52% for N0 disease compared with 21% for pathologic N2 disease. In contrast to many of the publications examining extended resection for SVC invasive malignancy, Suzuki and colleagues [4] differentiated 5-year survival with SVC invasion by direct tumor extension (36%) from those with SVC invasion by metastatic lymph nodes (6.6%). This separation may be artificial when induction therapy obscures tissue boundaries as a treatment effect. This distinction was poorly characterized in our patient series, even in the absence of neoadjuvant therapy. Several authors [4, 13, 14] have observed no correlation between T N M nodal status and survival after SVC resection for lung cancer. The conflicting data speak to statistical weakness of small sample sizes. The intraoperative management of SVC resection and reconstruction was relatively uniform in this clinical series. All circumferential SVC resections were performed with ringed PTFE (median size, 14; range, 8 to 18 mm) without a vascular shunt. Size was determined by extent of venous resection and the nature of the distal anastomosis to conform to native brachiocephalic vein or SVC. Other conduit options include tubularized bovine pericardium, spiral saphenous vein graft [15], and more recently, cryopreserved arterial allograft [16]. The overall thrombosis rate of PTFE reconstruction of the SVC has been reported to be 14% to 24% within 3 to 5 years [3, 5]. Most thromboses were observed within the first month of resection and reconstruction. The thrombotic risk is higher when SVC revascularization occurs in


the presence of venous collaterals. We observed an overall SVC thrombosis rate of 10% (2 of 19) with a median follow-up of 45 months. Both patients experienced early thrombosis despite anticoagulation within 12 to 24 hours postoperatively. One patient underwent primary suture repair of the SVC and another patient underwent reconstruction with a 12-mm ringed PTFE conduit to the right brachiocephalic vein. The small conduit may have contributed to thrombosis. Although venous Doppler studies were not routine after 30 days, no late symptomatic SVC thrombosis was observed. Coumadin was prescribed to 12 of 19 patients (63%) at discharge, with an average anticoagulation time of 3 to 6 months. Patients who underwent partial resection with suture or pericardial patch repair were often treated solely with enteric-coated aspirin (325 mg) for up to 3 months. Our preference was for unilateral reconstruction of the brachiocephalic veins, with satisfactory long-term patency. In contrast, Shintani and colleagues [17] recommend bilateral brachiocephalic reconstruction due to a thrombosis rate exceeding 50% at 5 to 26 months, particularly with unilateral left venous reconstruction. All patients in the Shintani series received Coumadin anticoagulation for 6 months or longer. Efforts were made to clamp the SVC proximal to the azygous vein to preserve collateral circulation and reduce cerebral edema. Clamping at the cavoatrial junction was routinely avoided to reduce the risk of sinoatrial node injury. Hemodynamic compromise during clamping was uncommon and less concerning in the 2 patients whose SVC was chronically stenosed or occluded before operation. SVC resection and reconstruction was performed after intravenous volume expansion and the use of pharmacologic vasoconstrictors. Although the use of SVC shunts during complete caval occlusion has been described [18], we have not used them. One strategy to reduce caval occlusion time is to perform the distal anastomosis directly to the right atrial appendage by using a Satinsky clamp on the atrium. The proximal venous anastomosis can be per-

Table 3. English Literature Review (1994 to 2007) of Patients Undergoing Superior Vena Cava Resection or Reconstruction for Malignant Disease First Author

Year

No.

Lung Cancer, No.

N2 Disease, No. (%)

Prosthetic Graft, No.

Mortality, %

5-Year Survival, %

MGH Spaggiari Suzuki Shargall Spaggiari Spaggiari Fukuse Dartevelle Thomas Tsuchiya

2007 2004 2004 2004 2000 1997 1997 1994 1994

19 70 40 23 109 6 11 22 15 32

9 52 40 15 109 6 11 6 15 32

3 (33) 21 (40) 15 (38) 7 (47) 55 (50) 2 (33) NR 2 (33) 6 (40) NR

12 25 11 9 28 3 3 22 2 7

5 7.7 10 14 12 0 2.4 7 7 22

30 31 24 37a 21 NR 15 (3 yrs) 31a 24 NR

a

Estimated from reported Kaplan-Meier survival curves within the study.

MGH ⫽ Massachusetts General Hospital;

NR ⫽ not reported.

formed last, thereby reducing central venous clamp time to that necessary for the proximal anastomosis. In most cases, SVC resection and reconstruction was performed first, followed by right-sided bronchopulmonary resections, including pneumonectomy, carinal pneumonectomy, or resections with proximal pulmonary artery invasion. This sequence requires careful attention to avoid bacterial or tumor cell contamination of the prosthetic graft. In the setting of malignancy, an autotransfusion device is not recommended. Venous clamp times were kept at less than 50 minutes, except in 1 patient. Another patient (50-minute SVC clamp time) sustained a transient right hemiparesis on postoperative day 2 while in atrial fibrillation due to an embolic middle cerebral artery occlusion. According to experimental data derived in 1989, 60 minutes of SVC occlusion was physiologically tolerated in a nonhuman primate model [19]; however, Dartevelle and colleagues [18] reported poor tolerance in humans when SVC clamping time exceeded 45 minutes. Our series confirmed a 5-year survival of 30% and 56% for extended resection of lung and anterior mediastinal neoplasms, respectively, found to involve the SVC. This is congruent with previously published series [1–5, 12, 13, 14, 20] (Table 3). The extended resections were associated with acceptable morbidity and mortality. Our experience suggests that the need for SVC reconstruction should not be considered a contraindication for resection of a bronchopulmonary or mediastinal neoplasm in an otherwise potentially curable patient, provided a complete resection can be achieved. Financial support for this study was provided by the Division of Thoracic Surgery at the Massachusetts General Hospital. We would like to acknowledge our clinical research coordinators, Sheila Cann, RN, and Diane Davies, RN, for helping to compile the data derived from the Thoracic Surgery database. We would also like to acknowledge Jimmie Honings, MD, for his assistance with the Kaplien-Meier survival analyses.


4.

5. 6. 7. 8.

9.

10. 11.

12. 13. 14.

15.

16. 17.

References 1. Spaggiari L, Regnard, J, Magdeleinat P, Jauffret B, Puyo P, Levasseur P. Extended resections for bronchogenic carcinoma invading the superior vena cava system. Ann Thorac Surg 2000;69:233– 6. 2. Thomas P, Magnan PE, Moulin G, Giudicelli R, Fuentes PE. Extended operation for lung cancer invading the superior vena cava. Eur J Cardiothoracic Surg 1994;8:177– 82. 3. Dartavelle PG, Chapelier AR, Pastorino U, et al. Long-term follow-up after prosthetic replacement of the superior vena

18. 19. 20.

397

cava combined with resection of mediastinal-pulmonary malignant tumors. J Thorac Cardiovasc Surg 1991;102:259 – 65. Suzuki K, Asamura H, Watanabe S, Tsuchiya R. Combined resection and superior vena cava for lung carcinoma: prognostic significance of patterns of SVC invasion. Ann Thor Surg 2004;784:1184 –9. Spaggiari L, Leo F, Veronesi G, et al. Superior vena cava resection for lung can mediastinal malignancies: a single center experience with 70 cases. Ann Thorac Surg 2007;83:223–30. Chen KN, Xu SF, Gu ZD, et al. Surgical treatment of complex malignant anterior medisational tumors invading the superior vena cava. World J Surg 2006;302:162–70. Moutain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710 –7. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007;28: 706 –14. Spaggiari L, Thomas P, Magdeleinat P, et al. Superior vena cava resection with prosthetic replacement for non-small cell lung: long term results of a multicentric study. Eur J Cardiothorac Surg 2002;21:1080 – 6. Garcia A, Flores RM. Surgical management of tumors invading the superior vena cava. Ann Thorac Surg 2008;85:2144 – 6. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:243– 65S. Tsuchiya R, Asamaura H, Kondo H, Goya T, Naruke T. Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 1994;57:960 –5. Spaggiari L, Magdeleinat P, Kondo H, et al. Results of superior vena cava resection for lung cancer, analysis of prognostic factors. Lung Cancer 2004;44:339 – 46. Shargall Y, de Perrot M, Keshavjee S, et al. 15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer. Lung Cancer 2004;45:357– 63. Doty DB. Bypass of superior vena cava: six years’ experience with spiral vein graft for obstruction of superior vena cava due to benign and malignant disease. J Thorac Cardiovasc Surg 1982;833:326 –38. Gomez-Caro A, Martinez E, Rodriguez A, et al. Cryopreserved arterial allograft reconstruction after excision of thoracic malignancies. Ann Thorac Surg 2008;86:1753– 61. Shintani Y, Ohta M, Minami M, et al. Long-term graft patency after replacement of the brachiocephalic veins combined with resection of mediastinal tumors. J Thorac Cardiovasc Surg 2005;129:809 –12. Dartevelle P, Macchiarini P, Chapelier A. Technique of superior vena cava resection and reconstruction. Chest Surg Clin N Am 1995;5:345–58. Masuda J, Ogata T, Kikuchi K. Physiological changes during temporary occlusion of the SVC in cynomolgus monkeys. Ann Thorac Surg 1989;47:890 – 6. Fukuse T, Wada H, Hitomi S. Extended operation for nonsmall cell lung cancer invading great vessels and left atrium. Eur J. Cardiothorac Surg 1997;11:664 –9.

INVITED COMMENTARY The article by Lanuti and colleagues [1] is important not only in terms of content but also because it offers further evidence that superior vena cava (SVC) resection is indicated to treat pulmonary and mediastinal malignancies. Technically speaking, the article confirms the feasibility of resection without cardiopulmonary support in all patients if selection is appropriate. © 2009 by The Society of Thoracic Surgeons Published by Elsevier Inc

I would like to add our personal contribution on a biologic prosthesis we routinely use in all patients undergoing SVC resection. Our first patient with lung cancer to receive a bovine pericardial tube was operated on in 2003. He is still alive without any anticoagulant regimen, with a fully patent prosthesis, and no graft calcification. To date, we have used biologic bovine pericardial patch in 8 patients, and 0003-4975/09/$36.00 doi:10.1016/j.athoracsur.2009.06.001

GENERAL THORACIC
